AmericanPeptide
Catalog/PE 22-28

PE 22-28

Also known as PE22-28 · spadin analog

A short spadin-derived peptide that blocks the TREK-1 potassium channel, studied as a fast-acting antidepressant and neuroprotective tool.

Research refreshed

Overview

PE 22-28 is a seven-residue peptide derived from spadin, the natural fragment of the sortilin propeptide that blocks the TREK-1 (TWIK-related potassium) channel. TREK-1 blockade is studied as a mechanism for rapid antidepressant action and for neuroprotection, and PE 22-28 was developed as a shortened, more stable spadin analog to probe that pathway. It is a preclinical research peptide with no human data and no approval.

Background

Spadin was identified as an endogenous peptide that blocks TREK-1, a potassium channel whose activity restrains serotonergic signaling. Blocking it produced fast antidepressant-like effects in mice, which made the pathway interesting as an alternative to monoamine-reuptake drugs. PE 22-28 is a short, optimized fragment of spadin designed to keep that TREK-1 activity in a more stable, drug-like peptide.

Research on PE 22-28 spans antidepressant models and, separately, neuroprotection in ischemic (stroke) models where TREK-1 modulation is relevant. The work is preclinical; there is no clinical trial, no human safety data, and no approval. This page is a research and educational reference.

Mechanism

Blockade of the TREK-1 background potassium channel, which modulates serotonergic neuron excitability; TREK-1 inhibition is associated with antidepressant-like effects and neuroprotection in animal models.

Key research findings

  • TREK-1 blocker — a spadin-derived peptide that inhibits the TREK-1 potassium channel.
  • Fast antidepressant mechanism — TREK-1 blockade produces rapid antidepressant-like effects in animal models.
  • Neuroprotection — studied in ischemic/stroke models alongside its mood effects.
  • Preclinical — no human data; not FDA-approved.

How PE 22-28 is made

Behind every vial of PE 22-28 is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how PE 22-28, specifically, is brought into being.

  1. On paper first

    PE 22-28 begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    PE 22-28 is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.

  3. Purity is won here

    The crude mixture — PE 22-28 plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of PE 22-28 proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of PE 22-28 — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

A short linear heptapeptide, straightforward to make by solid-phase synthesis. Purity is governed by removing deletion sequences over a short chain; the harder question is identity — a 7-mer is easy to synthesize and easy to mislabel, so mass spectrometry against the stated sequence is the meaningful check.

Standard synthesis
Storage
Store lyophilized, frozen, and protected from light; refrigerate reconstituted peptide and use within a short window. A short peptide in solution degrades faster than its lyophilized form.
Handling
Reconstitute gently without vortexing. With a seven-residue sequence, confirm identity by mass spectrometry — short peptides are easy to make incorrectly and easy to mislabel.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Depression models
  • TREK-1 channel pharmacology
  • Neuroprotection (stroke models)

Research-area guides

Latest research

Recent clinical trials and publications mentioning PE 22-28, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.

Frequently asked questions

What is PE 22-28?+

A short peptide derived from spadin that blocks the TREK-1 potassium channel, studied as a fast-acting antidepressant and neuroprotective agent in preclinical models.

How does it relate to spadin?+

It is a shortened, stabilized fragment of spadin designed to retain spadin’s TREK-1-blocking activity in a more drug-like peptide.

Is there human evidence?+

No — the research is in animal models. There is no clinical trial or human safety data.

Is it approved?+

No. This page is a research and educational reference, not medical advice.

Related peptides

Peptide Agent

Ask the Agent about PE 22-28

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.